AIDS research gets federal funding renewal at VUMC

by Bill Snyder
O&AN Contributor

Clinical AIDS research at Vanderbilt University Medical Center got a welcome shot in the arm this past week with the notice that federal support will continue at least through 2013.

The Vanderbilt HIV/AIDS Clinical Trials Unit will receive approximately $1.5 million during each of the next seven years from the National Institute of Allergy and Infectious Diseases (NIAID) to pursue studies of potential HIV vaccines and new AIDS treatments.

“This is another major milestone for HIV research at Vanderbilt, and certifies our place in the top tier of this field,” said Richard T. D'Aquila, M.D., who directs the Vanderbilt AIDS Center and the Division of Infectious Diseases.

“Because of the extraordinary accomplishments of our large team of skilled clinical researchers, we have been chosen to continue as one of the select few academic medical centers that will help to advance HIV prevention and treatment through these critical clinical trials during this tight funding environment,” D'Aquila said.

“We will do everything possible to develop a vaccine, and sustain efforts to ensure a long, high quality life for those already infected.”

Last June, the NIAID announced a restructuring of six clinical trials networks that focus on different aspects of HIV treatment and prevention. Sten Vermund, M.D., Ph.D., director of the Vanderbilt Institute for Global Health, was appointed principal investigator of the HIV Prevention Trials Network (HPTN), which conducts prevention trials throughout the world.

On Monday, the institute announced that 60 clinical trial units in the United States and 14 other countries, including Vanderbilt's, have been selected to participate in the restructured system. An additional 13 units will be funded in the coming months, NIAID officials said.

Vanderbilt's is relatively unique, D'Aquila said, because it includes the Vaccine Clinical Research Site, part of the HIV Vaccine Trials Network, and a Therapeutics Clinical Research Site, part of the AIDS Clinical Trials Group network.

“This reflects our collaborative culture, and definitely helps us to be efficient and gain intellectual synergies,” said D'Aquila, the Addison B. Scoville Jr. Professor of Medicine and professor of Microbiology and Immunology.

“It is my view that we need to attack HIV on every front — every possible approach to prevention, as well as improving chemotherapy and immunotherapy.”

Vanderbilt's Vaccine Clinical Research Site is currently led by Peter Wright, M.D., chief of the Division of Pediatric Infectious Diseases, and has been a leading site for research on potential HIV vaccines since 1987. On July 1, Wright will be succeeded by associate director Spyros Kalams, M.D.

Similarly, the Therapeutics Clinical Research Site, led by David Haas, M.D., has been a leading site in the testing and development of new AIDS treatments for the past six years.

“The real credit goes to the teams of study coordinators, nurses, patient educators, and laboratory personnel led by Drs. Haas, Wright, and Kalams,” D'Aquila said.

They include Kyle Rybczyk, MSN, FNP, vaccine study coordinator; Laurie Lebo, Ph.D., research manager for the Therapeutics Clinical Research Site; Janet Nicotera, R.N., BSN, networks and research coordinator for the Clinical Trials Unit; Michael Morgan, FNP; Vicki Bailey, R.N.; Brenda Jackson, R.N.; Fred Nicotera; Jeanne Schroder; Josh Barnes, Katie Crumbo, R.N.; and Dan Kuninsky.

The vaccine and AIDS treatment sites are integral components of the Vanderbilt AIDS Center, which also includes the NIH-funded Vanderbilt-Meharry Center for AIDS Research (CFAR) project. Last fall, the CFAR received an additional five years of federal funding and was upgraded from developmental to full center status.

Another Clinical Trials Unit in Tennessee, at St. Jude Children's Research Hospital in Memphis, has received federal funding. It is part of the International Maternal, Pediatric and Adolescent AIDS Clinical Trials network.

For more information, go to, and click on Clinical Trials Units and Clinical Research Sites.

WhistlePig + Alfa Romeo F1

SHOREHAM, VT (September 13, 2023) — WhistlePig Whiskey, the leaders in independent craft whiskey, and Alfa Romeo F1 Team Stake are waving the checkered flag on a legend-worthy release that’s taking whiskey to G-Force levels. The Limited Edition PiggyBack Legends Series: Alfa Romeo F1 Team Stake Barrel is a high Rye Whiskey selected by the Alfa Romeo F1 Team Stake drivers, with barrels trialed in their wind tunnel to ensure a thrilling taste in every sip.

The third iteration in WhistlePig’s Single Barrel PiggyBack Legends Series, the Alfa Romeo F1 Team Stake Barrel is bottled at 96.77 proof, a nod to Valtteri Bottas’ racing number, 77, and the precision of racing. Inspired by Zhou Guanyu, the first Chinese F1 driver, this Rye Whiskey is finished with lychee and oolong tea. Herbal and floral notes of the oolong tea complement the herbaceous notes of WhistlePig’s signature PiggyBack 100% Rye, rounded out with a juicy tropical fruit finish and a touch of spice.

Keep readingShow less
by Spectrum Medical Care Center

Nurse Practitioner Ari Kravitz

When I started medical transition at 20 years old, it was very difficult to get the care I needed for hormone replacement therapy because there are very few providers trained in starting hormones for trans people, even though it’s very similar to the hormones that we prescribe to women in menopause or cisgender men with low testosterone.

I hope more providers get trained in LGBTQ+ healthcare, so they can support patients along their individual gender journey, and provide the info needed to make informed decisions about their body. I’ve personally seen my trans patients find hope and experience a better quality of life through hormone replacement therapy.

Keep readingShow less

Descanso Resort swimming pool and lounge area

Descanso Resort, Palm Springs' premier destination for gay men, just received Tripadvisor's highest honor, a Travelers' Choice "Best of the Best" award for 2023. Based on guests' reviews and ratings, fewer than 1% of Tripadvisor's 8 million listings around the world receive the coveted "Best of the Best" designation. Descanso ranked 12th in the top 25 small inns and hotels category in the United States. Quite an accomplishment!

Open less than two years, Descanso Resort offers gay men a relaxing and luxurious boutique hotel experience just minutes away from Palm Springs' buzziest restaurants, nightclubs, and shopping. Descanso has quickly established itself as a top destination for sophisticated gay travelers, earning hundreds of 5-star guest reviews and consistently ranking in Trapadvisor's top positions alongside brother properties Santiago Resort and Twin Palms Resort.

Keep readingShow less